Merck
MRK
Market cap $269B

106.18 USD

-0.16

0.15%

Updated Oct 22, 10:48 AM EDT

1 day

-0.15%

5 days

-4.34%

1 month

-8.17%

3 months

-15.52%

6 months

-16.35%

Year to date

-6.23%

1 year

2.74%

5 years

30.60%

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 11 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

20% more call options, than puts

Call options by funds: $1.96B | Put options by funds: $1.64B

17% more repeat investments, than reductions

Existing positions increased: 1,562 | Existing positions reduced: 1,338

2% more first-time investments, than exits

New positions opened: 175 | Existing positions closed: 172

0% more funds holding

Funds holding: 3,452 [Q1] → 3,455 (+3) [Q2]

0.15% less ownership

Funds ownership: 77.17% [Q1] → 77.01% (-0.15%) [Q2]

6% less capital invested

Capital invested by funds: $258B [Q1] → $242B (-$15.3B) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 237 [Q1] → 190 (-47) [Q2]

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$115

8%

upside

Avg. target

$140

32%

upside

High target

$155

46%

upside

11 analyst ratings

9 positive

82%

2 neutral

18%

0 negative

0%

Bernstein	8%upside $115	Market Perform Initiated	17 Oct 2024
UBS Colin Bristow 33% 1-year accuracy 5 / 15 met price target	28%upside $136	Buy Maintained	9 Oct 2024
Truist Securities Robyn Karnauskas 57% 1-year accuracy 20 / 35 met price target	24%upside $132	Buy Maintained	9 Oct 2024
Barclays Carter Gould 54% 1-year accuracy 20 / 37 met price target	32%upside $140	Overweight Maintained	7 Oct 2024
Cantor Fitzgerald Louise Chen 56% 1-year accuracy 69 / 124 met price target	46%upside $155	Overweight Reiterated	3 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 42 articles about MRK published over the past 30 days

3 Attractive Biotechs With Recent Positives

The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.

3 Attractive Biotechs With Recent Positives

Zacks Investment Research

Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?

We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.

Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?

Zacks Investment Research

Gilead, MRK Report Data From Investigational Combination Study for HIV

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Gilead, MRK Report Data From Investigational Combination Study for HIV

CNBC Television

Oakmark's Bill Nygren on stocks to play today

Bill Nygren, Oakmark portfolio manager, joins 'Money Movers' to discuss the rationale behind the stock position's Nygren has added, why value is the most important factor, and much more.

Oakmark's Bill Nygren on stocks to play today

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor. These late-breaking data were presented during an oral session at IDWeek 2024, t.

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Proactive Investors

Merck RSV jab has the potential to protect infants

Merck & Co Inc's (NYSE:MRK, ETR:6MK) experimental treatment for respiratory syncytial virus (RSV) has shown positive results in a mid- to late-stage trial, moving the company closer to seeking regulatory approval. The treatment, clesrovimab, aims to protect infants from RSV, a leading cause of hospitalizations in newborns and responsible for hundreds of infant deaths annually.

Merck RSV jab has the potential to protect infants

Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing respiratory syncytial virus (RSV) infections in infants.

Merck's RSV antibody for infants shows over 60% efficacy in mid-late-stage study

Merck says experimental RSV treatment protected infants in trial, paving way for potential approval

Merck said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial. The pharmaceutical giant could emerge as a new competitor in the market for treatments against RSV, which causes hundreds of infant deaths each year.

Merck says experimental RSV treatment protected infants in trial, paving way for potential approval

Merck's Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Infants.

Merck's Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants

Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's CAPVAXIVE (Pneumo. 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease.

Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

See News Rankings

Charts implemented using Lightweight Charts™